Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3547090 | 0.85 | CACNA1H (0.36) | CACNA1HCACNA1BKMT2A | |
| SCHEMBL3551597 | 0.79 | CACNA1B (0.36) | CACNA1HCACNA1BKMT2A | |
| SCHEMBL3553474 | 0.77 | KMT2A (0.47) | CACNA1HCACNA1BKMT2A | |
| SCHEMBL3541459 | 0.75 | CACNA1B (0.36) | CACNA1HCACNA1BKMT2A | |
| SCHEMBL3548171 | 0.75 | TSHR (0.43) | CACNA1HCACNA1BKMT2A | |
| SCHEMBL3541852 | 0.73 | ACE (0.39) | CACNA1HCACNA1BKMT2A | |
| SCHEMBL3553015 | 0.73 | POLB (0.40) | CACNA1HCACNA1BKMT2A | |
| SCHEMBL3542513 | 0.71 | OPRM1 (0.40) | CACNA1BKMT2A | |
| SCHEMBL3546210 | 0.69 | CACNA1H (0.37) | CACNA1H | |
| SCHEMBL3547224 | 0.69 | HSD17B10 (0.38) | CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1828169-A2 | UREA INHIBITORS OF MAP KINASES | Locus Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060167247-A1 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| WO-2006062982-A2 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167247-A1 | Urea inhibitors of MAP kinases | MAPK1, MAP3K1, MAP3K20 | CACNA1H 4873/4885CACNA1B 4869/4885KMT2A 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.